We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
2
2 active
Approvals
0
Total approvals
Agencies
Regulatory bodies
Founded
1995
Active, not recruiting
100.0%
No approval data available
- The neuroregeneration therapy market is projected to grow at a 5.3% CAGR from 2024 to 2034, with North America leading the expansion due to advanced healthcare infrastructure and strong research funding. - Recent breakthroughs include Biogen's promising gene therapy trials for Parkinson's disease and BrainStorm Cell Therapeutics' regulatory approval for stem cell-based ALS treatment. - Artificial intelligence, stem cell research, and gene therapy applications are reshaping the therapeutic landscape, with major pharmaceutical companies forming strategic partnerships to accelerate innovation.
